Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 14/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12610265 | 0.96 | HIF1A (1.00) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL4522145 | 0.90 | HIF1A (0.75) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL1593340 | 0.90 | HIF1A (0.75) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL1593540 | 0.89 | HIF1A (0.74) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL12610042 | 0.89 | HIF1A (0.86) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL4527044 | 0.88 | HIF1A (0.72) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL14303700 | 0.87 | HIF1A (0.83) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL1593685 | 0.87 | HIF1A (0.70) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL12703792 | 0.86 | HIF1A (0.69) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL12610116 | 0.86 | HIF1A (1.00) | HIF1AALDH1A1SMN1; SMN2LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20160271133-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271133-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160015710-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160015710-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-01-21 | — | — | US | disclosed |
| US-20140227221-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140227221-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8575143-B2 | 3-aryl-substituted quinazolones, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8518959-B2 | Quinoxaline derivatives as antitumor agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-7615554-B2 | Erastin and erastin binding proteins, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2009002553-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1999116-A2 | 3-ARYL-SUBSTITUTED QUINAZOLONES, AND USES THEREOF | Prolexys Pharmaceuticals, Inc. (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2008013987-A2 | N-ALKYL SUBSTITUTED PIPERAZINYLMETHYLQUINAZOLINONES AND AZEPANYLMETHYLQUINAZOLINONES | PROLEXYS PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013840-A2 | ERASTIN ANALOGS AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
| WO-2007076087-A2 | 3-ARYL-SUBSTITUTED QUINAZOLONES, AND USES THEREOF | PROLEXYS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271133-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | MCL1, SLC11A2, MEN1 | HIF1A 214/4885ALDH1A1 3199/4885SMN1; SMN2 1948/4885 |
| US-20070161644-A1 | Erastin analogs and uses thereof | ERAP2, ERAP1, ERAL1 | HIF1A 928/4885ALDH1A1 1049/4885SMN1; SMN2 1759/4885 |
| US-20140227221-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | MCL1, BCL3, DDIT3 | HIF1A 275/4885ALDH1A1 1600/4885SMN1; SMN2 2093/4885 |
| US-20160015710-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | MCL1, SLC11A2, MEN1 | HIF1A 214/4885ALDH1A1 3199/4885SMN1; SMN2 1948/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | HIF1A 726/4885ALDH1A1 2857/4885SMN1; SMN2 4247/4885 |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | VDAC3, VDAC2, VDAC1 | HIF1A 2396/4885ALDH1A1 4035/4885SMN1; SMN2 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.